Rockwell Medical, Inc., together with its associated companies, operates as a biopharmaceutical firm specializing in treatments for chronic and end-stage kidney disease. The company provides a range of therapies and products aimed at addressing iron deficiency and supporting hemodialysis procedures, serving markets both within the United States and internationally. A key offering includes its Triferic line (Triferic Dialysate and Triferic AVNU), an innovative iron replacement therapy. This therapy is designed to replenish iron and maintain healthy hemoglobin levels in dialysis patients, notably without increasing existing iron stores. Beyond iron management, Rockwell Medical manufactures, sells, and distributes a comprehensive range of hemodialysis concentrates. These include various acid concentrates such as CitraPure (citric), Dri-Sate (dry), and RenalPure (liquid), alongside a dry acid concentrate mixer, and powder bicarbonate concentrates like RenalPure and SteriLyte. These crucial products are vital for sustaining life in dialysis patients by facilitating the removal of toxins and the replacement of essential nutrients in their bloodstream. The company further supplies ancillary items critical for hemodialysis procedures. This extensive catalog comprises blood tubing, fistula needles, dialyzers, pharmaceuticals, specialized component kits, dressings, cleaning agents, filtration salts, and other necessary provisions utilized by hemodialysis providers. Looking to the future, Rockwell Medical is actively developing additional therapeutic candidates. These include treatments for hospitalized individuals suffering from acute heart failure, as well as solutions for home infusion therapy, enabling patients to receive intravenous medications in a home setting. The company primarily serves medium and small-sized dialysis chains, as well as independent dialysis centers. Established in 1996, Rockwell Medical, Inc. maintains its corporate headquarters in Wixom, Michigan.

NASDAQHealthcareDrug Manufacturers - Specialty & Generic
أحدث البيانات المتاحة
7.685 US$
+0.115 US$ · +1.52%
جلسة التداول العادية
7.685 US$
+0.115 US$ · +1.52%
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
Rockwell Medical, Inc., together with its associated companies, operates as a biopharmaceutical firm specializing in treatments for chronic and end-stage kidney disease. The company provides a range of therapies and products aimed at addressing iron deficiency and supporting hemodialysis procedures, serving markets both within the United States and internationally. A key offering includes its Triferic line (Triferic Dialysate and Triferic AVNU), an innovative iron replacement therapy. This therapy is designed to replenish iron and maintain healthy hemoglobin levels in dialysis patients, notably without increasing existing iron stores. Beyond iron management, Rockwell Medical manufactures, sells, and distributes a comprehensive range of hemodialysis concentrates. These include various acid concentrates such as CitraPure (citric), Dri-Sate (dry), and RenalPure (liquid), alongside a dry acid concentrate mixer, and powder bicarbonate concentrates like RenalPure and SteriLyte. These crucial products are vital for sustaining life in dialysis patients by facilitating the removal of toxins and the replacement of essential nutrients in their bloodstream. The company further supplies ancillary items critical for hemodialysis procedures. This extensive catalog comprises blood tubing, fistula needles, dialyzers, pharmaceuticals, specialized component kits, dressings, cleaning agents, filtration salts, and other necessary provisions utilized by hemodialysis providers. Looking to the future, Rockwell Medical is actively developing additional therapeutic candidates. These include treatments for hospitalized individuals suffering from acute heart failure, as well as solutions for home infusion therapy, enabling patients to receive intravenous medications in a home setting. The company primarily serves medium and small-sized dialysis chains, as well as independent dialysis centers. Established in 1996, Rockwell Medical, Inc. maintains its corporate headquarters in Wixom, Michigan.
نطاق اليوم
السعر الحالي 7.685 US$
نطاق 52 أسبوعًا
السعر الحالي 7.685 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
بيع
تقييم
50
قيمة عادلة
المشاعر
59
مختلط
المخاطر
77
مخاطر مرتفعة
الزخم
17
هبوط قوي
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
Rockwell Medical, Inc., together with its associated companies, operates as a biopharmaceutical firm specializing in treatments for chronic and end-stage kidney disease. The company provides a range of therapies and products aimed at addressing iron deficiency and supporting hemodialysis procedures, serving markets both within the United States and internationally. A key offering includes its Triferic line (Triferic Dialysate and Triferic AVNU), an innovative iron replacement therapy. This therapy is designed to replenish iron and maintain healthy hemoglobin levels in dialysis patients, notably without increasing existing iron stores. Beyond iron management, Rockwell Medical manufactures, sells, and distributes a comprehensive range of hemodialysis concentrates. These include various acid concentrates such as CitraPure (citric), Dri-Sate (dry), and RenalPure (liquid), alongside a dry acid concentrate mixer, and powder bicarbonate concentrates like RenalPure and SteriLyte. These crucial products are vital for sustaining life in dialysis patients by facilitating the removal of toxins and the replacement of essential nutrients in their bloodstream. The company further supplies ancillary items critical for hemodialysis procedures. This extensive catalog comprises blood tubing, fistula needles, dialyzers, pharmaceuticals, specialized component kits, dressings, cleaning agents, filtration salts, and other necessary provisions utilized by hemodialysis providers. Looking to the future, Rockwell Medical is actively developing additional therapeutic candidates. These include treatments for hospitalized individuals suffering from acute heart failure, as well as solutions for home infusion therapy, enabling patients to receive intravenous medications in a home setting. The company primarily serves medium and small-sized dialysis chains, as well as independent dialysis centers. Established in 1996, Rockwell Medical, Inc. maintains its corporate headquarters in Wixom, Michigan.
نطاق اليوم
السعر الحالي 7.685 US$
نطاق 52 أسبوعًا
السعر الحالي 7.685 US$
الربحية كنسبة مئوية من الإيرادات المعلنة.
الإيرادات
الدخل التشغيلي
صافي الدخل
| البند (USD) | السنة المالية 2025 | السنة المالية 2024 | السنة المالية 2023 | السنة المالية 2022 | السنة المالية 2021 |
|---|---|---|---|---|---|
| الإيرادات | 69.26 مليون USD | 101.49 مليون USD | 83.61 مليون USD | 72.81 مليون USD | 61.93 مليون USD |
| تكلفة البضاعة المباعة | 57.56 مليون USD | 84.01 مليون USD | 74.91 مليون USD | 68.73 مليون USD | 64.35 مليون USD |
| الربح الإجمالي | 11.7 مليون USD | 17.48 مليون USD | 8.7 مليون USD | 4.08 مليون USD | −2.42 مليون USD |
| البحث والتطوير | — | 19 ألف USD | 1.11 مليون USD | 3.12 مليون USD | 6.84 مليون USD |
| مصاريف البيع والمصاريف العمومية والإدارية | 16.39 مليار USD | 16.86 مليون USD | 14.27 مليون USD | 17.74 مليون USD | 21.08 مليون USD |
| نفقات التشغيل | 16.39 مليون USD | 16.88 مليون USD | 15.37 مليون USD | 20.86 مليون USD | 27.92 مليون USD |
| دخل الفوائد | 234 ألف USD | 92 ألف USD | 211 ألف USD | 33 ألف USD | 22 ألف USD |
| مصاريف الفوائد | 1.12 مليون USD | 1.25 مليون USD | 2.3 مليون USD | 1.94 مليون USD | 2.36 مليون USD |
| الاستهلاك والإطفاء | 2.19 مليون USD | 2.18 مليون USD | 1.44 مليون USD | 576 ألف USD | 2.52 مليون USD |
| الدخل التشغيلي | −4.69 مليون USD | 608 ألف USD | −6.67 مليون USD | −16.78 مليون USD | −30.34 مليون USD |
| صافي الدخل | −5.31 مليون USD | −480 ألف USD | −8.44 مليون USD | −18.68 مليون USD | −32.67 مليون USD |
تم تحديث حقائق الشركة 13 أكتوبر 2026.
أحدث النتائج المعلنة
أحدث النتائج المعلنة
قد تتغير تقديرات المحللين الخارجيين، وهي ليست توصيات من GoAI.
متوسط الهدف
20.00 US$
ارتفاع محتمل بنسبة 160.25%| الإجراء | تاريخ النفاذ | تفاصيل | تاريخ التسجيل | تاريخ الدفع |
|---|---|---|---|---|
تقسيم الأسهم | 1 يوليو 2026 | 1:10 | — | — |
تقسيم الأسهم | 13 مايو 2022 | 1:11 | — | — |
ساري 1 يوليو 2026
1:10
ساري 13 مايو 2022
1:11
صناديق متداولة تفصح عن تعرضها لهذا السهم.
المحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.